Richwood Adderall will be available again under IND exemption for hyperactivity disorder.
RICHWOOD ADDERALL AVAILABLE UNDER IND EXEMPTION for patients with attention deficit hyperactivity disorder until the company can get approval of an NDA supplement for the combination amphetamine product. Under an IND approved March 3, distribution is limited to "only those patients who have been on Adderall/Obetrol during the past year and whose physicians certify that they do not respond satisfactorily to currently marketed single ingredient amphetamines," FDA said in a March 6 document explaining the regulatory status of the product. Richwood has resumed Adderall production and expects patients to begin receiving the drug under the IND by March 17.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth